Korean J Psychopharmacol.
2004 Jun;15(2):135-143.
Efficacy, Safety, and Tolerability of Quetiapine in Patients with Schizophrenia
- Affiliations
-
- 1Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea.
- 2Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Korea.
Abstract
- Atypical antipsychotics have an improved tolerability profile, and are less likely to cause debilitating extrapyramidal symptoms (EPS) than are the conventional antipsychotics. Quetiapine, the fourth atypical antipsychotic, was marketed in Korea as well as in the United States and is also available in over 70 countries worldwide. Quetiapine has been shown to be effective and well tolerated in patients particularly vulnerable to EPS related to conventional antipsychotics. In this article, we review the clinical trials examining the efficacy, safety, and tolerability of quetiapine in treating patients with schizophrenia.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Open Clinical Trial to Assess the Efficacy and Safety of Quetiapine in Patients of Schizophrenia
- Comparison of Efficacy and Safety between Risperidone and Quetiapine in Schizophrenia and Schizoaffective Disorder: A Pilot Study
- Quetiapine, Mood Stabilizer?
- Clinical Trials of Risperidone in the Patients with Schizophrenia: Comparison with Other Antipsychotics
- Pharmacotherapy of Bipolar Disorder with Quetiapine: A Recent Literature Review and an Update
